ACCME weighs pharma-free labeling

Share this article:
The Accreditation Council for Continuing Medical Education (ACCME) is considering offering an accreditation flagging CME as being free of drug and device industry support—a kind of Good Housekeeping Seal for CME.

The accrediting body issued a call for public comment on the proposal, saying: “The ACCME recognizes that some stakeholders want to differentiate between CME that does include relationships with industry from CME that does not include relationships with industry. To clarify this differentiation, the ACCME will consider creating a new designation and review process for providers that wish to identify their program of CME as one that does not utilize funds from commercial interests that have been donated to support continuing medical education.”

Such programs, ACCME said, would not accept any commercial support for any CME activity or any part of its CME program and would not use funds from advertising or promotion paid for by a commercial interest to underwrite costs of CME.

ACCME is also considering a similar designation for programs that do not use teachers or authors “that have acted for a commercial interest in promotional and marketing activities.”

And ACCME is considering setting up an independent CME funding entity that would collect and disburse unrestricted CME funds from industry sources. The group is accepting public comments on all three proposals through May 21.

Earlier in April, the accrediting body announced that it was no longer considering a ban on commercial support of CME.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...